Want to see ONCY full AI Analyst Report?
Top Page
Oncolytics Biotech
(NASDAQ:ONCY)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.79
▼(-8.26% Downside)
Action:Reiterated
Date:08/18/26
The score is primarily constrained by weak financial performance (no revenue, widening losses, and ongoing cash burn alongside negative equity), which dominates the risk profile. Technicals also remain pressured with the stock below key moving averages. Positive FDA/regulatory momentum and other supportive corporate updates partially offset these concerns but do not fully counterbalance the funding and listing risks.
Positive Factors
FDA-Backed Registrational Path
FDA alignment reduces regulatory uncertainty around pelareorep in RAS-mutant colorectal cancer and supports a more efficient transition from the ongoing study to a potential pivotal program, provided interim clinical data are supportive.
Negative Factors
No Commercial Revenue
The absence of product revenue leaves Oncolytics dependent on financing, partnerships, or future milestones to fund operations, making its financial outlook highly dependent on clinical and regulatory execution.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA-Backed Registrational Path
FDA alignment reduces regulatory uncertainty around pelareorep in RAS-mutant colorectal cancer and supports a more efficient transition from the ongoing study to a potential pivotal program, provided interim clinical data are supportive.
Read all positive factors
Oncolytics Biotech (ONCY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$109.10M
Dividend YieldN/A
Average Volume (3M)1.42M
Price to Earnings (P/E)―
Beta (1Y)1.32
Revenue GrowthN/A
EPS Growth2.05%
CountryUS
Employees29
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.34
Shares Outstanding127,510,506
10 Day Avg. Volume2,066,048
30 Day Avg. Volume1,415,275
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)-22.05
Price to Sales (P/S)0.00
P/FCF Ratio-5.71
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside481.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
Oncolytics Biotech Business Overview & Revenue Model
Company Description
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the tr...
How the Company Makes Money
Oncolytics Biotech is a clinical-stage drug developer and, as such, it does not primarily generate revenue from selling approved products; instead, its ability to generate revenue generally depends on non-recurring or development-linked sources. I...
Oncolytics Biotech Earnings Call Summary
Earnings Call Date:May 14, 2025
(Q1-2025)
| % Change Since: |
Next Earnings Date:Oct 30, 2026
Earnings Call Sentiment Positive
The earnings call reflects a strong positive sentiment with significant advancements in clinical data and strategic financial moves. The highlights, particularly in clinical trial progress and promising data across several cancer types, outweigh the challenges such as the ongoing CEO search and reduced R&D spending.Positive Updates
Clinical Data Exceeds Expectations
Oncolytics Biotech's clinical data for pelareorep continues to exceed expectations, particularly in difficult-to-treat malignancies such as pancreatic cancer, breast cancer, and anal carcinoma.
Negative Updates
Ongoing CEO Search
The search for a new CEO is still ongoing, indicating a potential leadership gap in the interim period.
Read all updates
Q1-2025 Updates
Positive
Negative
Clinical Data Exceeds Expectations
Oncolytics Biotech's clinical data for pelareorep continues to exceed expectations, particularly in difficult-to-treat malignancies such as pancreatic cancer, breast cancer, and anal carcinoma.
Read all positive updates
Company Guidance
During the first quarter conference call for Oncolytics Biotech in 2025, the company provided guidance on several key metrics related to the development of their cancer therapeutic, pelareorep (pela). They reported cash and cash equivalents of $15.3 million, which is expected to provide financial runway through the third quarter of 2025. Net cash used in operating activities was $6.5 million, a decrease from $7.5 million in the same period last year. General and administrative expenses remained consistent at $3 million, while research and development expenses decreased to $4.1 million from $5.7 million in Q1 2024. The net loss for the quarter was $6.7 million, or $0.08 per share, compared to $6.9 million or $0.09 per share in the previous year. The company also announced a $20 million share purchase agreement with Alumni Capital to extend their financial runway. Oncolytics is advancing their clinical trials, particularly focusing on breast and pancreatic cancer, with promising efficacy data from randomized Phase 2 studies and plans for future registrational opportunities.Oncolytics Biotech Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -38.13M | -28.66M | -25.45M | -25.17M | -19.55M | -25.78M |
| Net Income | -38.21M | -28.76M | -22.79M | -20.92M | -18.30M | -26.30M |
Balance Sheet | ||||||
| Total Assets | 7.67M | 10.40M | 20.19M | 38.82M | 37.33M | 45.88M |
| Cash, Cash Equivalents and Short-Term Investments | 4.12M | 7.14M | 15.94M | 34.91M | 32.14M | 41.26M |
| Total Debt | 448.00K | 772.51K | 1.06M | 423.00K | 373.00K | 655.00K |
| Total Liabilities | 13.84M | 15.62M | 14.20M | 11.26M | 10.83M | 9.78M |
| Stockholders Equity | -6.17M | -5.21M | 5.98M | 27.56M | 26.50M | 36.10M |
Cash Flow | ||||||
| Free Cash Flow | -28.93M | -20.12M | -20.06M | -21.45M | -17.25M | -22.72M |
| Operating Cash Flow | -28.92M | -20.11M | -19.88M | -21.44M | -17.21M | -22.43M |
| Investing Cash Flow | -12.29K | -6.00K | -174.00K | 15.24M | -15.03M | -286.00K |
| Financing Cash Flow | 22.25M | 14.12M | 5.03M | 24.12M | 8.99M | 33.02M |
Oncolytics Biotech Technical Analysis
Neutral
0.86
Price Trends
0.86
Positive
0.89
Negative
0.94
Negative
Market Momentum
<0.01
Negative
56.49
Neutral
83.68
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ONCY, the sentiment is Neutral. The current price of 0.86 is above the 20-day moving average (MA) of 0.81, above the 50-day MA of 0.86, and below the 200-day MA of 0.94, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 56.49 is Neutral, neither overbought nor oversold. The STOCH value of 83.68 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ONCY.
Oncolytics Biotech Risk Analysis
Oncolytics Biotech disclosed 68 risk factors in its most recent earnings report. Oncolytics Biotech reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oncolytics Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $222.13M | 1.21 | 72.96% | ― | -100.00% | ― | |
53 Neutral | $523.51M | -8.03 | -75.35% | ― | 220.34% | 55.73% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $26.45M | -0.61 | -84.91% | ― | ― | -28.83% | |
42 Neutral | $109.10M | -3.42 | 1020.21% | ― | ― | 2.05% | |
42 Neutral | $94.15M | -7.84 | 44.67% | ― | -96.72% | -253.97% | |
42 Neutral | $368.27M | -1.58 | -87.95% | ― | -100.00% | 14.08% |
* Healthcare Sector Average
ONCY
Oncolytics Biotech
0.85
-0.22
-20.56%
ATOS
Atossa Therapeutics
2.64
-8.67
-76.66%
ORMP
Oramed Pharm
5.10
3.05
148.78%
ATRA
Atara Biotherapeutics
9.25
-3.11
-25.16%
ZNTL
Zentalis Pharmaceuticals
3.88
2.12
120.45%
PRLD
Prelude Therapeutics
6.34
5.03
383.97%
Oncolytics Biotech Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Oncolytics Biotech gains FDA alignment on REO 033 trial
Positive
Aug 18, 2026
On August 18, 2026, Oncolytics Biotech Inc. reported it had received written feedback from the U.S. Food and Drug Administration on the design of a potential pivotal Part B expansion of its REO 033 study in second-line RAS-mutant, microsatellite s...
Delistings and Listing ChangesRegulatory Filings and Compliance
Oncolytics Biotech Faces Nasdaq Minimum Bid Price Noncompliance
Negative
Jul 24, 2026
On July 20, 2026, Oncolytics Biotech disclosed that it received a notice from Nasdaq indicating its shares had traded below $1.00 for 30 consecutive business days, putting the company out of compliance with the exchange’s minimum bid price r...
Business Operations and StrategyRegulatory Filings and Compliance
Oncolytics Biotech gains FDA Fast Track for pelareorep
Positive
Jul 20, 2026
On July 20, 2026, Oncolytics Biotech announced that the U.S. Food and Drug Administration granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for patients with inoperable, locally recurrent or metastatic squamou...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Oncolytics Biotech advances REO 033 colorectal cancer program
Positive
Jul 13, 2026
On July 13, 2026, Oncolytics Biotech reported clinical and regulatory progress for its REO 033 randomized controlled trial of pelareorep plus FOLFIRI and bevacizumab in second-line RAS-mutant, microsatellite stable metastatic colorectal cancer, bu...
Business Operations and Strategy
Oncolytics Biotech Secures New Pelareorep Manufacturing Patent
Positive
Jun 16, 2026
On June 16, 2026, Oncolytics Biotech Inc. announced that the U.S. Patent and Trademark Office issued a new patent covering key aspects of its proprietary commercial manufacturing process for pelareorep, extending intellectual property protection i...
Business Operations and StrategyExecutive/Board Changes
Oncolytics Biotech Strengthens Leadership with New COO, Director
Positive
Jun 2, 2026
On June 1, 2026, Oncolytics Biotech appointed veteran clinical operations executive John McAdory as Chief Operating Officer, expanding his remit to oversee clinical operations, development activities, preclinical RD, and strategic partnerships, af...
Business Operations and StrategyProduct-Related Announcements
Oncolytics Highlights Pelareorep-RAS Combo Preclinical Cancer Results
Positive
Jun 1, 2026
On June 1, 2026, Oncolytics Biotech Inc. reported initial preclinical data showing that its investigational immunotherapy pelareorep, when combined with RAS inhibitor modalities in a solid tumor model, produced greater anti-tumor activity than eit...
Business Operations and Strategy
Oncolytics Highlights Pelareorep Immune Activation Data at ASCO
Positive
May 22, 2026
On May 22, 2026, Oncolytics Biotech announced that translational data from its GOBLET and AWARE-1 trials will be presented at the 2026 American Society of Clinical Oncology Annual Meeting, highlighting pelareorep’s ability to activate both i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.